Acorda Therapeutics, Inc. (ACORQ)
Aug 22, 2024 - ACORQ was delisted (reason: shares cancelled)
0.0100
0.00 (0.00%)
Inactive · Last trade price on Aug 23, 2024
Acorda Therapeutics Employees
Acorda Therapeutics had 102 employees as of December 31, 2023. The number of employees decreased by 9 or -8.11% compared to the previous year.
Employees
102
Change (1Y)
-9
Growth (1Y)
-8.11%
Revenue / Employee
$1,133,961
Profits / Employee
-$2,582,598
Market Cap
12.42K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 102 | -9 | -8.11% |
| Dec 31, 2022 | 111 | -7 | -5.93% |
| Dec 31, 2021 | 118 | -50 | -29.76% |
| Dec 31, 2020 | 168 | -176 | -51.16% |
| Dec 31, 2019 | 344 | -130 | -27.43% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
ACORQ News
- 1 year ago - Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics - Business Wire
- 1 year ago - Acorda Therapeutics Announces Delisting from Nasdaq - Business Wire
- 1 year ago - Acorda Therapeutics Announces Nasdaq Delisting Notification - Business Wire
- 1 year ago - Acorda Therapeutics shares sink nearly 40% after bankruptcy filing - Market Watch
- 1 year ago - Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement - Business Wire
- 1 year ago - Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024 - Business Wire
- 1 year ago - Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024 - Business Wire
- 1 year ago - Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025 - Business Wire